NCT00955773 - A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 17, 2009

Primary Completion Date

November 8, 2011

Study Completion Date

November 8, 2011

Conditions

Cancer

Interventions

DRUG

GSK1120212 plus everolimus

Dose escalation will begin at low doses of GSK1120212 and everolimus, then gradually increase in future cohorts. Dose escalation will continue until a recommended combination dose is identified. The recommended combination dose will be used to treat pancreatic and lung cancer patients in later groups in this study.

Trial Locations (3)

37203

GSK Investigational Site, Nashville

75970

GSK Investigational Site, Paris

78229

GSK Investigational Site, San Antonio